Revenue grew 40% YoY to Rs 307.2 crore in Q3FY25 driven by doubling of CDMO business driven by R&D and business development efforts.
Gross margins for the quarter stood at 71.5% and adjusted EBITDA margins stood at 38.7%.
The Hyderabad-based company said it is seeing strong demand across stages on the back of secular macro tailwinds.
It said two molecules added this quarter in which one molecule advanced to Phase 3 and one directly added to Phase III (laterals addition), increasing total active Phase 3 projects to 15 with 9 molecules.
It also said a previously highlighted positive readout on Phase III molecule has now met the primary endpoint for a second indication and onboarded a new strategic customer – one of the top five global pharma leaders for early-to-mid-phase projects.
-
Stock Trading
Maximise Returns by Investing in the Right Companies
-
Stock Trading
Market 104: Options Trading: Kickstart Your F&O Adventure
-
Stock Trading
Technical Analysis for Everyone – Technical Analysis Course
-
Stock Trading
Stock Markets Made Easy
-
Stock Trading
Renko Chart Patterns Made Easy
-
Stock Trading
Candlesticks Made Easy: Candlestick Pattern Course
-
Stock Trading
Market 101: An Insight into Trendlines and Momentum
-
Stock Trading
Markets 102: Mastering Sentiment Indicators for Swing and Positional Trading
-
Stock Trading
Market 103: Mastering Trends with RMI and Techno-Funda Insights
-
Stock Trading
Dow Theory Made Easy
-
Stock Trading
ROC Made Easy: Master Course for ROC Stock Indicator
-
Stock Trading
RSI Made Easy: RSI Trading Course
-
Stock Trading
Heikin Ashi Trading Tactics: Master the Art of Trading
-
Stock Trading
RSI Trading Techniques: Mastering the RSI Indicator
-
Stock Trading
Introduction to Technical Analysis & Candlestick Theory
“We continue to make business development efforts and remain focused on high-value CDMO offerings and expansion in niche technology platforms in line with our strategic vision,’ said Vivek Sharma, executive chairman.”Our investments in ADCs and oligonucleotides with fast underlying market growth position us well for sustained mid and long-term growth,” Sharma added.
